메뉴 건너뛰기




Volumn 23, Issue 17, 2013, Pages 4751-4760

Peripherally restricted CB1 receptor blockers

Author keywords

AM6545; Cannabinoid receptor blocker; CB1 antagonist; Diabetes; Inverse agonist; JD5037; Liver diseases; Metabolic disorders; Obesity; Peripherally restricted; Rimonabant; Silent antagonist

Indexed keywords

BRAIN RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; LIPOPROTEIN LIPASE; PLACEBO; RIMONABANT; TARANABANT; TM 38837; UNCLASSIFIED DRUG;

EID: 84881368891     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.06.066     Document Type: Review
Times cited : (78)

References (87)
  • 72
    • 84881374370 scopus 로고    scopus 로고
    • 7TM Pharma Press Release: November 11, 2010. 7TM Pharma successfully conducts clinical Phase I trial of its first in class peripheral CB1 receptor antagonist TM38837 demonstrating restriction from the human CNS
    • 7TM Pharma Press Release: November 11, 2010. 7TM Pharma successfully conducts clinical Phase I trial of its first in class peripheral CB1 receptor antagonist TM38837 demonstrating restriction from the human CNS.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.